Studying clonal evolution of myeloid malignancies using induced pluripotent stem cells.

Current Opinion in Hematology
Sergei Doulatov, Eirini P Papapetrou


Myeloid malignancies comprise a spectrum of genetically heterogeneous disorders marked by the stepwise acquisition of somatic mutations and clonal evolution. The blood and bone marrow of patients typically consists of a mix of different clones and subclones along the path of clonal evolution that cannot be deconvoluted with most current approaches. Here, we review the application of induced pluripotent stem cell (iPSC) technology to the study of the clonal architecture and clonal evolution of these diseases, focusing on myelodysplastic syndromes and acute myeloid leukemia. Reprogramming to pluripotency allows capture of the genomes of single somatic cells into stable iPSC lines. In addition, precise genome editing can introduce specific driver mutations, isolated, and in combinations, into normal iPSCs. Studies utilizing these approaches have elucidated the clonal composition and mutational order in patients with myeloid neoplasms. Importantly, they have also enabled functional interrogation of the cellular and molecular consequences of individual mutations and their combinations and allowed testing of the effects of drugs on distinct disease clones. Human iPSCs are important tools to elucidate the mechanisms of progression fro...Continue Reading


Oct 15, 2011·The New England Journal of Medicine·E PapaemmanuilUNKNOWN Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium
Jul 24, 2012·Cell·John S WelchRichard K Wilson
Aug 31, 2012·Science Translational Medicine·Max JanRavindra Majeti
Sep 14, 2013·Blood·Elli PapaemmanuilUNKNOWN Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium
Feb 20, 2014·Proceedings of the National Academy of Sciences of the United States of America·M Ryan Corces-ZimmermanRavindra Majeti
Nov 27, 2014·The New England Journal of Medicine·Siddhartha JaiswalBenjamin L Ebert
Nov 27, 2014·The New England Journal of Medicine·Giulio GenoveseSteven A McCarroll
Dec 2, 2014·Nature Biotechnology·Thorsten M SchlaegerGeorge Q Daley
Apr 4, 2015·Science Translational Medicine·Amy L PaguiriganJerald P Radich
Aug 23, 2016·Nature Communications·Andrew L YoungTodd E Druley
Feb 10, 2017·Science Translational Medicine·Sergei DoulatovGeorge Q Daley
May 18, 2017·Nature·Ryohichi SugimuraGeorge Q Daley
Feb 6, 2018·Cell Stem Cell·Robert L BowmanRoss L Levine
Jul 11, 2018·Nature·Sagi AbelsonLiran I Shlush
Jul 11, 2018·Nature Medicine·Pinkal DesaiDuane C Hassane
Jan 24, 2019·Blood·Seishi Ogawa
May 1, 2019·JCI Insight·Melisa Ruiz-GutierrezAkiko Shimamura
May 3, 2019·Haematologica·Allan BekeEric Solary
Aug 28, 2019·Cold Spring Harbor Perspectives in Medicine·Eirini P Papapetrou
Nov 2, 2019·Science·Siddhartha Jaiswal, Benjamin L Ebert
May 21, 2020·Blood·Andrew J Menssen, Matthew J Walter
Jun 17, 2020·Experimental Hematology·Andriana G Kotini, Eirini P Papapetrou

❮ Previous
Next ❯

Related Concepts

Related Feeds


This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.